How Lipitor Works on Proteins
Lipitor (atorvastatin) inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis: the conversion of HMG-CoA to mevalonate.[1] This protein's active site binds atorvastatin tightly, blocking substrate access and reducing cholesterol production in the liver.
Which Specific Protein Does It Target?
The primary target is HMG-CoA reductase (HMGCR), a transmembrane glycoprotein in the endoplasmic reticulum. Atorvastatin mimics HMG-CoA, fitting into the enzyme's catalytic pocket and causing a conformational change that halts activity. No other proteins are directly inhibited at therapeutic doses; downstream effects reduce levels of isoprenoids like farnesyl pyrophosphate, indirectly impacting small GTPases (e.g., Rho and Ras proteins) by limiting their prenylation and membrane localization.[2]
What Happens Downstream from Disruption?
Inhibiting HMGCR depletes mevalonate intermediates, disrupting:
- Prenylation of GTPases: Proteins like RhoA, Rac1, and Ras lose lipid anchors, impairing cell signaling, migration, and proliferation. This contributes to Lipitor's pleiotropic effects like anti-inflammation.
- Dolichol and ubiquinone synthesis: Affects glycoprotein synthesis and mitochondrial function, though less prominently.
These are indirect; Lipitor does not bind these proteins directly.[3]
Are There Off-Target Protein Effects?
Clinical data show no major disruptions to non-statin-related proteins. Rare myopathy links to genetic variants in SLCO1B1 (a transporter protein affecting statin uptake), but this modulates exposure, not direct inhibition. No evidence of broad proteomic disruption in standard use.[4]
How Does This Compare to Other Statins?
All statins target HMGCR, but atorvastatin has higher potency and lipophilicity, leading to broader tissue penetration and stronger GTPase effects versus hydrophilic simvastatin or pravastatin.[5]
[1]: Lipitor mechanism - DrugBank
[2]: HMGCR inhibition review - Nature Reviews Drug Discovery
[3]: Statin pleiotropy - Circulation Research
[4]: SLCO1B1 and statin myopathy - NEJM
[5]: Statin comparisons - Lancet